NCT03561558View on ClinicalTrials.gov

Bioequivalence Study of Ibuprofen D, Oral Suspension, 200 mg/5ml and Nurofen®, Oral Suspension 100 mg/5 ml in Healthy Volunteers Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 11, 2018

Primary Completion Date

June 24, 2018

Study Completion Date

June 25, 2018

Conditions
Healthy
Interventions
DRUG

Ibuprofen D

Ibuprofen D, oral suspension, 200 mg / 5ml, manufactured by LLC Pharmtechnology, Belarus

DRUG

Nurofen® for Children

Nurofen® for Children, Oral Suspension, 100 mg / 5 ml, marketed by Reckitt Benckiser Healthcare International Ltd, UK

Trial Locations (1)

150010

"State Autonomous Healthcare Facility of the Yaroslavl Region Clinical Hospital No. 2", Yaroslavl

All Listed Sponsors
collaborator

ClinPharmInvest, LLC

OTHER

lead

Pharmtechnology LLC

INDUSTRY

NCT03561558 - Bioequivalence Study of Ibuprofen D, Oral Suspension, 200 mg/5ml and Nurofen®, Oral Suspension 100 mg/5 ml in Healthy Volunteers Under Fasting Conditions | Biotech Hunter | Biotech Hunter